Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol

• Published in: PloS one 2011-01, Vol.6 (1), p.e15874
• Main Authors: Teissier, Elodie, Zandomeneghi, Giorgia, Loquet, Antoine, Lavillette, Dimitri, Lavergne, Jean-Pierre, Montserret, Roland, Cosset, François-Loïc, Böckmann, Anja, Meier, Beat H, Penin, François, Pécheur, Eve-Isabelle
• Format: Article
• Language: English
• Subjects: Antiviral agents; Antiviral Agents - pharmacology; Binding; Binding Sites; Biology; Cell fusion; Cell Membrane - chemistry; Cell Membrane - metabolism; Drug development; Drugs; Ethanol; Fluorescence; Glycoproteins; Glycoproteins - chemistry; Glycoproteins - metabolism; Hepatitis; Hepatitis C; Hepatitis C virus; Indoles - pharmacokinetics; Indoles - pharmacology; Influenza; Life Sciences; Lipids; Liposomes; Magnetic Resonance Spectroscopy; Medicine; Membrane fusion; Membrane Lipids - metabolism; Membrane proteins; Membranes; Molecular structure; NMR; Nuclear magnetic resonance; Peptides; Phospholipids; Phospholipids - metabolism; Physical chemistry; Protein binding; Proteins; Residues; Sensors; Tryptophan; Virus Internalization - drug effects; Viruses
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0015874

The broad-spectrum antiviral arbidol (Arb) inhibits cell entry of enveloped viruses by blocking viral fusion with host cell membrane. To better understand Arb mechanism of action, we investigated its interactions with phospholipids and membrane peptides. We demonstrate that Arb associates with phospholipids in the micromolar range. NMR reveals that Arb interacts with the polar head-group of phospholipid at the membrane interface. Fluorescence studies of interactions between Arb and either tryptophan derivatives or membrane peptides reconstituted into liposomes show that Arb interacts with tryptophan in the micromolar range. Interestingly, apparent binding affinities between lipids and tryptophan residues are comparable with those of Arb IC50 of the hepatitis C virus (HCV) membrane fusion. Since tryptophan residues of membrane proteins are known to bind preferentially at the membrane interface, these data suggest that Arb could increase the strength of virus glycoprotein's interactions with the membrane, due to a dual binding mode involving aromatic residues and phospholipids. The resulting complexation would inhibit the expected viral glycoprotein conformational changes required during the fusion process. Our findings pave the way towards the design of new drugs exhibiting Arb-like interfacial membrane binding properties to inhibit early steps of virus entry, i.e., attractive targets to combat viral infection.